In this episode, we examine Atrioventricular Septal Defect (AVSD), a spectrum of congenital heart malformations ranging from partial to complete defects caused by the abnormal development of endocardial cushions. We discuss the condition's strong genetic association with Trisomy 21 (Down syndrome) and explore the evolution of surgical interventions, specifically comparing the "Nunn" modified single-patch technique against traditional two-patch repairs. Finally, we review critical long-term outcomes, highlighting the lifelong need for surveillance due to risks of left atrioventricular valve regurgitation and atrial arrhythmias.

In this episode, we explore the science of Narcolepsy Type 1 (NT1), a neurological disorder defined by the autoimmune destruction of orexin-producing neurons in the hypothalamus. We unpack the critical genetic link to the HLA-DQB1*06:02 allele and how CD8+ T cells target specific brain cells to cause excessive sleepiness and cataplexy. We also discuss the diagnostic challenges—including an average seven-year delay—and the exciting shift toward mechanism-based therapies like the orexin receptor agonist TAK-861, which may soon offer the first treatment to functionally restore wakefulness signaling.

In this episode, we examine Congenital Diaphragmatic Hernia (CDH), a developmental defect where abdominal organs herniate into the chest, causing pulmonary hypoplasia and persistent pulmonary hypertension. We explore recent research revealing neurodevelopmental differences in survivors, specifically increased cortical thickness and cerebrospinal fluid volumes in children treated with extracorporeal membrane oxygenation (ECMO). The discussion also covers critical management strategies, such as "gentle ventilation" to avoid lung injury, the debated efficacy of inhaled nitric oxide, and the role of Vitamin A deficiency and genetic factors in the condition's etiology.

In this episode, we explore AL Amyloidosis (Primary Systemic Amyloidosis), a rare and aggressive plasma cell disorder where misfolded immunoglobulin light chains form toxic fibrils that damage vital organs, particularly the heart and kidneys. We discuss the critical importance of early diagnosis to halt irreversible organ failure, highlighting how cardiac involvement remains the primary driver of mortality and prognosis.

The episode examines the current standard of care, the Dara-CyBorD regimen (Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone), which has revolutionised treatment by inducing rapid and deep haematological responses. We also review the strict eligibility criteria for autologous stem cell transplantation (ASCT), a high-risk but potentially durable option for selected patients, and look ahead to emerging therapies like CAEL-101 designed to target and clear amyloid deposits directly.

In this episode, we explore idiopathic hypersomnia (IH), a rare chronic neurological disorder characterised by an inability to maintain wakefulness and 'sleep drunkenness' (severe sleep inertia) that persists despite prolonged, often unrefreshing sleep. We examine the profound burden IH places on cognitive function and daily safety, with patients frequently reporting debilitating 'brain fog' and a significantly elevated risk of motor vehicle accidents. Listeners will discover the complex pathophysiology behind the condition, particularly the 'GABA-related hypersomnia' hypothesis involving an endogenous somnogen in cerebrospinal fluid that enhances inhibitory signalling in the brain. Finally, we discuss the evolving management landscape, from lifestyle adjustments and the FDA-approved low-sodium oxybate to emerging investigational therapies like orexin-2 receptor agonists designed to restore wakefulness.

In this episode, we explore Peripartum Cardiomyopathy (PPCM), a rare, life-threatening form of heart failure defined by left ventricular systolic dysfunction that occurs near the end of pregnancy or in the months following delivery. We examine the prevailing "two-hit" model of pathogenesis, which suggests that oxidative stress triggers the cleavage of the nursing hormone prolactin into a toxic 16-kDa fragment that damages the heart's vasculature. We also discuss the "BOARD" treatment regimen, a disease-specific approach utilizing bromocriptine to inhibit prolactin production alongside anticoagulation and standard heart failure therapies. Finally, we look at the risks of relapse in subsequent pregnancies and how advanced echocardiographic markers like global longitudinal strain can improve risk stratification for women wishing to conceive again.

In this episode, we explore Polycythemia Vera (PV), a rare, chronic blood cancer driven by the JAK2 gene mutation that causes the bone marrow to produce an uncontrolled excess of red blood cells. We unpack the critical "thick blood" phenomenon that leads to the disease's primary mortality risk—thrombosis—and distinct symptoms like aquagenic pruritus (itching after warm water).

Listeners will learn about:

• Diagnosis: The WHO criteria, including elevated hemoglobin, bone marrow hypercellularity, and the hallmark low serum erythropoietin (EPO) levels.
• Risk Stratification: How age (over 60) and thrombosis history determine whether a patient is "high-risk".
• Management: The standard care pillars of phlebotomy and low-dose aspirin, alongside cytoreductive therapies like hydroxyurea and interferons for high-risk cases.
• Long-term Outlook: The risks of progression to myelofibrosis or acute myeloid leukemia (AML) and the emerging importance of monitoring clonal burden via the JAK2 variant allele frequency (VAF).

In this episode, we explore Retinitis Pigmentosa (RP), a group of rare, inherited retinal dystrophies affecting over 1.5 million people globally that cause progressive vision loss through the degeneration of photoreceptor cells. We examine the current therapeutic landscape, which is largely limited to supportive care and the single FDA-approved gene therapy, Luxturna, available only for patients with specific RPE65 mutations. Finally, we highlight promising advancements in the pipeline, including mutation-agnostic optogenetics to restore light sensitivity, stem cell therapies for tissue replacement, and neuroprotective agents like exosomes and rod-derived cone viability factor (RdCVF) to preserve remaining vision.

In this episode, we explore the critical challenge of neonatal sepsis, a leading cause of mortality in premature infants that demands a careful balance between rapid intervention and antimicrobial stewardship,. We examine the rising threat of antimicrobial resistance, particularly among Gram-negative pathogens like Klebsiella pneumoniae in neonatal intensive care units, where broad-spectrum antibiotic use contributes to the emergence of multidrug-resistant strains,. The discussion highlights diagnostic strategies, noting that while blood cultures remain the gold standard, clinicians are urged to discontinue antibiotics after 36 to 48 hours if cultures are sterile to prevent adverse outcomes like necrotising enterocolitis and microbiome disruption,. Finally, we review the long-term consequences for survivors, who face significantly elevated risks of neurodevelopmental impairments and cognitive deficits later in childhood.

In this episode on Spinal Cord Injury (SCI), we explore the critical "Time is Spine" rule: surgical decompression within 24 hours significantly increases the odds of neurological recovery. We decode the ASIA Impairment Scale, the clinical standard for grading injury severity from A (complete) to E (normal), and uncover the hidden danger of Autonomic Dysreflexia—a life-threatening blood pressure spike often triggered by simple irritants like a full bladder. Finally, we look to the future of repair, highlighting FDA-designated breakthroughs like "dancing molecules" and stem cell therapies (AST-OPC1) designed to regenerate damaged tissue.